

LITERATÚRA

1. Capatina C, Wass JH 60 Years Of Neuroendocrinology: Acromegaly. *J Endocrinol* 2015; 226: 141–160.
2. Sharma MD, Nguyen AV, Brown S et al. Cardiovascular disease in acromegaly. *Huostonmethodist.org/debakey-journal* 2007; 2: 64–67.
3. Matta MP, Caron P Acromegalic cardiomyopathy: a review of the literature. *Pituitary* 2003; 6: 203–207.
4. Kršek M Endokrinni choroby a jejich vliv na KV system. *Medical Tribune* 2015; XXX: 17.
5. Mosca S, Paolillo S, Colao A et al. Cardiovascular involvement inpatients affected by acromegaly: an appraisal. *Int J Cardiol* 2013; 167: 1712–1718.
6. Kahaly G, Olshausen KV, Mohr-Kahaly S et al. Arrhythmia profile in acromegaly. *Eur Heart J* 1992; 13: 51–56.
7. Vitale G, Pivonello R, Lombardi G et al. Cardiac abnormalities in acromegaly. *Pathophysiology and implications for management. Treat Endocrinol* 2004; 3: 309–318
8. Warszawski L, Kasuki L, Sá R et al. Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. *Pituitary* 2016; 19: 582–589.
9. Roca E, Mattogno PP, Porcelli Tet al. Plurihormonal ACTH-GH Pituitary Adenoma: Case Report and Systematic Literature Review. *World neurosurgery* 2018; 114: 158–164.
10. Colao A, Pivonello R, Grasso LF et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. *Eur J Endocrinol* 2011; 165: 713–721.
11. Jayasena C, Cominos A, Clarke H et al. The effects of long term GH and IGF-I exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. *Clin Endocrinol* 2011; 75: 220–225.
12. Colao A, Spinelli L, Marzullo P et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. *J Clin Endocrinol Metab* 2003; 88: 3196–3201.
13. Pereira AM, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. *J Clin Endocrinol Metab* 2004; 89: 71–75.
14. van der Klaauw AA, Bax JJ, Roelfsema F et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. *Growth Horm IGF Res* 2006; 16: 101–107.
15. Colao A, Marzullo P, Di Somma C et al. Growth hormone and the heart. *Clin Endocrinol* 2001; 54: 137–154.
16. Isgaard J, Tivesten A, Friberg P et al. The role of the GH/IGF-I axis for the cardiac function and structure. *Horm Metab Res* 1999; 31: 50–54.
17. Castellano G, Affuso F, Conza P Di et al. The GH/IGF-1 Axis and Heart Failure. *Curr Cardiol Rev* 2009; 5: 203–215.
18. Mendoza E, Malong CL, Tanchee-Ngo MJ et al. Acromegaly With Cardiomyopathy, Cardiac Thrombus and Hemorrhagic Cerebral Infarct: A Case Report of Therapeutic Dilemma With Review of Literature. *Int J Endocrinol Metab* 2015; 13: 1–4.
19. John jr. AJ, Laws ER Surgical Treatment of Pituitary Adenomas. Dostupné z <https://www.ncbi.nlm.nih.gov/books/NBK278983/>.
20. Hána V, Švancara J, Bandúrová L et al. Registry of sellar tumors - RESET: Diagnostic and therapy of acromegaly in Czech and Slovak republics in the 21st century. *Diabetes, metabolismus, endokrinologie a výživa* 2013; 16: 219–224.
21. Colao A, Pivonello R, Galderisi M et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. *J Clin Endocrinol Metab* 2008; 93: 2639–2646.
22. Sakai H, Tsuchiya K, Nakayama C et al. Improvement of endothelial dysfunction in acromegaly after transphenoidal surgery. *Endocr J* 2008; 55: 853–859.
23. Melmed S New therapeutic agents for acromegaly. *Nat Rev Endocrinol* 2016; 12: 90–98.
24. Katznelson L, Laws EL, Melmed S et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2014; 99: 3933–3951.
25. Zahr R, Fleseriu M Updates in Diagnosis and Treatment of Acromegaly. *European Endocrinology* 2018; 10: 57–61.
26. Carmichael JD et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. *J Clin Endocrinol Metab* 2014; 99: 1825–1833.
27. Colao A, Marzullo P, Cuocolo A et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long acting somatostatin analogue octreotide. *Clin Endocrinol* 2003; 58: 169–176.
28. Annamalai AK, Webb A, Kandasamy N et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. *J Clin Endocrinol Metab* 2013; 98: 1040–1050.
29. Colao A, Marzullo P, Ferone D et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. *J Clin Endocrinol Metab* 2000; 86: 3132–3140.
30. Colao A, Cuocolo A, Marzullo P et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. *J Clin Endocrinol Metab* 1999; 84: 17–23.
31. Akutsu H, Kreutzer J, Wasmeier G et al. Acromegaly per se does not increase the risk for coronary artery disease. *Eur J Endocrinol* 2010; 162: 879–886.
32. Colao A, Auriemma RS, Galdiero M et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor I levels, tumor shrinkage, and cardiovascular disease: a prospective study. *J Clin Endocrinol Metab* 2009; 94: 3746–3756.
33. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. *N Engl J Med* 2000; 342: 1171–1177.
34. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. *Lancet* 2001; 358: 1754–1759.
35. van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. *J Clin Endocrinol Metab* 2012; 97: 1589–1597.
36. Colao A, Pivonello R, Auriemma RS et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. *Eur J Endocrinol* 2006; 154: 467–477.
37. Auriemma RS, Pivonello R, De Martino MC et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. *Eur J Endocrinol* 2012; 168: 15–22.
38. De Martino MC, Auriemma RS, Brevetti G et al. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. *J Endocrinol Invest* 2010; 33: 663–670.
39. Pivonello R, Galderisi M, Auriemma RS et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. *J Clin Endocrinol Metab* 2007; 92: 476–482.
40. Kuhn E, Maione L, Bouchachi A et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. *Eur J Endocrinol* 2015; 173: 693–702.
41. Auriemma RS, Grasso LF, Galdiero M et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. *Endocrine* 2016; 55: 872–884.
42. Baldwin A, Cundy T, Butler J et al. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. *Acta Endocrinol* 1985; 1: 581–587.
43. Sninčák M Srdcové zlyhávanie v roku 2016 - novinky v odporúčaniach, súčasný stav, trendy. *Via practica* 2016; 13: 163–167.
44. Thomas J, Dattani A, Zemrak F et al. Renin-Angiotensin System. Blockade Improves Cardiac Indices in Acromegaly Patients. *Exp Clin Endocrinol Diabetes* 2017; 125: 365–367.
45. Bihan H, Espinosa C, Valdes-Socin H et al. Long-term outcome of patients with acromegaly and congestive heart failure. *J Clin Endocrinol Metab* 2004; 89: 5308–5313.
46. Silvermann CB, Baran A Dilated and Restrictive Cardiomyopathies. <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/dilated-restrictive-cardiomyopathy/>